Do you have multiple myeloma? Have you had a stem cell transplant? If so, you may be able to take part in a research study looking at the effectiveness of giving a drug called daratumumab, along with lenalidomide, after a stem cell transplant to patients with multiple myeloma.

This is a three-year research study for people with primary membranous nephropathy (primary MN). The study will test if combining belimumab and rituximab is effective in treating Primary MN.

To evaluate the safety and efficacy of a device removing lipids from the blood using an apheresis device in treating primary FSGS

If you have been treated with ANCA vasculitis and you are now in remission, you may be able to participate in a study to test if a specific blood test can help your doctor decide if you need maintenance therapy.

We are looking for patients with kidney disease and healthy controls (no kidney disease) to provide blood samples, fill out surveys, and provide health related information to help investigators learn more about how to better diagnose and treat kidney disease. The information you provide will go into a "library" of data for doctors and researchers across the world to use for research projects. If you are a kidney patient, we are able to use your information to find out if you are eligible for treatment studies/other studies in the future.

The purpose of this study is to learn more about three kidney diseases called nephrotic syndrome: Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN). By collecting health information and laboratory samples from individuals who have these diseases and by making this information available to researchers, we hope to gain new knowledge about these diseases and to find better treatments for them.

To test the effect of automated RBC exchange transfusion and standard of care compared with standard of care on the number of episodes of clinical worsening of sickle cell disease (SCD)requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 12 months in high risk adult SCD patients.

We have created this registry to provide an opportunity to study diagnostic capabilities, administration protocols and long-term effects of contrast-enhanced ultrasound (CEUS) of any organ.

Belatacept is a drug that helps kidney transplant recipients by preventing the body from rejecting the new organ. We want to compare how well belatacept works compared to the commonly used drug tacrolimus. To do this, we plan to study people who got kidney transplants in the United States from 2011 to 2020. By using two large databases, the United States Renal Data System, and the Scientific Registry of Transplant Recipients, we aim to understand how belatacept is used in real life. We are also interested in comparing how effective and safe is belatacept compared with tacrolimus after one year of administration. We will look at outcomes like how long the transplanted kidney will work, how long will the kidney transplant recipients live, how well your kidneys will work, the risk of organ rejection, and certain side effects to happen after transplant like blood cancer.

We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.